AVTX
NASDAQAvalo Therapeutics Inc.
Price$17.79+0.41 (+2.36%)
01:30 PM07:45 PM
News · 26 weeks98-30%
2025-12-282026-06-21
Mix6890d
- Insider35(51%)
- SEC Filings15(22%)
- Other11(16%)
- Analyst3(4%)
- Offering3(4%)
- Leadership1(1%)
Latest news
25 items- SECAvalo Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
- PRAvalo Therapeutics Appoints Ron Philip to Board of DirectorsWAYNE, Pa., June 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the appointment of Ron Philip to its Board of Directors. Mr. Philip brings more than 30 years of biopharmaceutical leadership to the Board, with a deep background in commercial and strategic execution, including guiding multiple companies through product launches and billion dollar exits. "We are thrilled to welcome Ron to the Board at this pivotal time for Avalo following our positive Phase 2 LOTUS topline results and transformative fina
- SECAvalo Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
- PRAvalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β AntibodyIND submission for AVTX-010 planned for the first half of 2027 WAYNE, Pa., June 16, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody (mAb) with the potential for development in hidradenitis suppurativa (HS) as well as additional inflammatory disorders. "Building on the strength of our abdakibart Phase 2 LOTUS topline data and our conviction in the IL-1β pathway, we believe developing a long-acting next-generation molecule is a natural
- INSIDERChief Strategy Officer Riley Jennifer covered exercise/tax liability with 588 shares, decreasing direct ownership by 1% to 39,696 units (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Legal Officer Varki Paul covered exercise/tax liability with 1,081 shares, decreasing direct ownership by 3% to 32,576 units (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Financial Officer Sullivan Christopher Ryan covered exercise/tax liability with 138 shares, decreasing direct ownership by 0.34% to 40,773 units (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Medical Officer Doyle Mittie covered exercise/tax liability with 1,084 shares, decreasing direct ownership by 2% to 51,776 units (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- SECAvalo Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
- ANALYSTBofA Securities initiated coverage on Avalo Therapeutics with a new price targetBofA Securities initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $35.00
- SECAvalo Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
- INSIDERSEC Form 4 filed by Director Lind Kevin Robert4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERSEC Form 4 filed by Director Truex Samantha4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERSEC Form 4 filed by Director Kaplan Gilla4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERSEC Form 4 filed by Director Kantoff Aaron4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERSEC Form 4 filed by Director Jain Rita4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERSEC Form 4 filed by Director Heffernan Michael Thomas4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Medical Officer Doyle Mittie exercised 679 shares at a strike of $8.04 and sold $10,864 worth of shares (679 units at $16.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Executive Officer Neil Garry Arthur was granted 100,200 shares, increasing direct ownership by 111% to 190,314 units (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Legal Officer Varki Paul was granted 24,300 shares, increasing direct ownership by 669% to 27,934 units (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Medical Officer Doyle Mittie was granted 43,500 shares, increasing direct ownership by 1,201% to 47,122 units (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Financial Officer Sullivan Christopher Ryan was granted 39,900 shares, increasing direct ownership by 9,433% to 40,323 units (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERChief Strategy Officer Riley Jennifer was granted 34,200 shares, increasing direct ownership by 1,288% to 36,855 units (SEC Form 4)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- PRAvalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)WAYNE, PA., May 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the Company granted an inducement award consisting of an option to purchase 34,000 shares of its common stock to one new employee (the "Option"). The award was approved by the Compensation Committee of the Board of Directors as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Option was granted on May 21, 2026 and has an exercise price of $16.60 per share, which is e
AVTX FAQ
6 questionsWhere does AVTX stock trade?
Avalo Therapeutics Inc. (AVTX) is listed on NASDAQ.What sector and industry is AVTX in?
Avalo Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Avalo Therapeutics Inc. go public?
Avalo Therapeutics Inc. (AVTX) completed its IPO in 2015.What are analysts saying about AVTX?
Avalo Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Buy with a $3500.00 price target on 2026-06-12. Recent price targets range from $2500.00 to $4800.00.What companies are similar to AVTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare AVTX side-by-side with any of them on Quantisnow.How can I track AVTX on Quantisnow?
Quantisnow aggregates Avalo Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AVTX to receive live email and push alerts on every new disclosure.